Compare Merck & Co., Inc. (MRK) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs UiPath Inc — how do they compare? Merck & Co., Inc. trades at $148.01 (market cap $366.28B), while UiPath Inc trades at $13.57 (market cap $7.26B). The key difference: Merck & Co., Inc. is far larger — about 50.5× UiPath Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| MRK | PATH | |
|---|---|---|
Market Cap | $366.28B | $7.26B |
Sector | Health | Technology |
52-Week High | $156.43 | $19.29 |
52-Week Low | $77.60 | $9.38 |
Enterprise Value | $413.04B | $6.05B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
UiPath (PATH) is trading at $14.01, down 7.77% in the last 24 hours amid mixed technical signals and earnings volatility. The stock shows improving fundamentals with revenue growing from $892M in 2022 to $1.43B in 2025, though profitability remains negative with a -$73.69M net income. Recent Q2 2026 earnings beat expectations but guidance concerns triggered a selloff, with technical indicators showing bearish momentum despite oversold RSI conditions.
PATH presents a turnaround opportunity with strong revenue growth and improving margins, but faces execution risks in competitive AI automation. Analyst consensus targets $17.38 (24% upside) despite cautious ratings, with institutional interest growing. Key risks include sustained profitability challenges and AI competition, while positive cash flow trends and strategic positioning in enterprise automation offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
